INS and type 2 diabetes mellitus: When mice with type 2 diabetes mellitus (T2DM) were administered an analog of CGRP, their circulating glucagon-like peptide-1 (GLP-1) level increased, their fasting blood glucose, fasting insulin and glycosylated hemoglobin (HbA1c) levels decreased, and their food intake and body weight decreased significantly [74].